MedWatch

MC2 and Almirall clear crucial obstacle to psoriasis treatment in Europe

Psoriasis cream Wynzora has safely traversed the decentralized procedure route to approval in Europe, which paves the way for individual national health authorities to vouch for the treatment.

Photo: MC2 Therapeutics / PR

Danish company MC Therapeutics' psoriasis cream Wynzora has cleared another obstacle on the way to the EU markets.

MC2 and its partner, dermatology company Almirall, announce in a press release that Wynzora has successfully completed the decentralized procedure.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs